AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

Psychedelic therapies are emerging as promising treatments for various mental health conditions, such as depression, post-traumatic stress disorder (PTSD), anxiety and substance-use disorders.

The recall was initiated due to the discovery of N-nitroso-duloxetine, a chemical impurity classified as a nitrosamine.

Anxiety and depression are more common among people with Crohn’s disease, and they can worsen symptoms. Here’s why and ways ...

Identified as “Mr. A,” the man experienced “suffering and functional decline” following three vaccinations for SARS-CoV-2. He also suffered from depression, post-traumatic stress disorder, anxiety and ...

Persistent brain fog, characterised by a feeling of mental cloudiness or haziness, can be a red flag for an underlying health ...

I do not want our work to be weaponized,” said Johanna Olson-Kennedy, a doctor involved in the study. “It has to be exactly ...

According to the results of a new study conducted by researchers from the National University Arturo Jauretche in Argentina, ...

Pink cocaine, a popular party drug, has been in the news since it was found in former One Direction singer Liam Payne’s ...

A prescription digital therapeutic for insomnia was associated with significant improvements in sleep, depression, and anxiety.

The leader of the long-running study said that the drugs did not improve mental health in children with gender distress and ...

Dealing with a menstrual cycle is no easy feat. But for those coping with PMDD, the intense emotional, physical and ...